The ups and downs of pharmacopoeial harmonization
This article was originally published in Scrip
As drug regulation becomes more global in nature, international trade continues to expand, and drug substances are increasingly manufactured using biotechnology techniques, the European Pharmacopoeia Commission is taking steps to develop more harmonized international quality standards, and is also extending its reach to encompass the quality of finished products rather than just pharmaceutical substances.
You may also be interested in...
A World Health Organization negotiating body has agreed to develop a “zero draft” of the proposed pandemic treaty for discussion at a meeting of WHO member states in February next year. But the international pharmaceutical industry has reiterated its concerns about some of the proposals being put forward.
EU member states are calling for a formal approach to making vaccine procurement agreements more flexible, saying that any further delay will “undermine the trust of society in vaccination and vaccines.”
Two documents published by the European Commission outline proposals to prepare for future health emergencies such as pandemics and the impact of antimicrobial resistance, with next-generation vaccines and novel or repurposed therapeutics high on the agenda.